Camp4 Therapeutics (CAMP) Return on Capital Employed (2024 - 2026)

Camp4 Therapeutics has disclosed Return on Capital Employed across 3 years of filings, most recently posting 55.29% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 55.29%, up 2789.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 55.29% (up 2789.0% YoY), and the FY2025 annual result was 63.67%, up 2942.0% from the prior year.
• Return on Capital Employed came in at 55.29% for Q1 2026 at Camp4 Therapeutics, up from 60.7% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 55.29% in Q1 2026 to a low of 131.93% in Q4 2024.
• The 3-year median for Return on Capital Employed is 85.74% (2025), against an average of 87.91%.
• Across the five-year window, Return on Capital Employed surged 7124 bps in 2025 and soared 2789 bps in 2026, its largest moves.
• Camp4 Therapeutics' Return on Capital Employed stood at 131.93% in 2024, then jumped by 54 bps to 60.7% in 2025, then grew by 9 bps to 55.29% in 2026.
• The last three Return on Capital Employed figures came in at 55.29% (Q1 2026), 60.7% (Q4 2025), and 88.32% (Q3 2025), per Business Quant data.